Clinical Trial Update: Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing erlotinib versus placebo after chemoradiotherapy in stage III non-small cell lung cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-09-06